{
  "docId": "019de073-a59c-77cf-8e75-229e6c5c9530",
  "docSlug": "74412512a1adb89488775a4a2b6a1b7b",
  "documentTitle": "Avenue Therapeutics | IPO Presentation Deck | 30 slides",
  "authorId": "avenue-therapeutics",
  "authorName": "Avenue Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 17,
  "pageCount": 30,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a comparison to Cerevel's darigabat and lorazepam.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/17",
  "deckHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530",
  "deckJsonHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json",
  "deckAnchorHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "list",
      "text": "BAER-101/AZD7325 was tested in over 700 subjects (healthy volunteers and patients)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0014a117-c175-4275-80c2-d4b1fc33552a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.39
      },
      "kind": "list",
      "text": "In two Phase 2 studies, BAER-101 was tested in patients with generalized anxiety disorder (GAD), but missed the primary endpoint",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d758810-57ca-4f44-9ff7-96ccf01d6b66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "BAER-101 was also tested in a human abuse liability study where risk abuse with BAER-101 appeared lower than lorazepam (a BZD)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa6e3b6f-6b2c-455d-b0e2-dc4a93e5e282",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.89,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "list",
      "text": "A sub analysis of the data with removal of dropouts and non-compliant patients (as measured by drug plasma levels), showed: a dose-related anxiolytic signal; a correlation between average exposure and efficacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bed5ed3b-3ef1-4005-99b1-99ae7015739c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.89,
        "x": 0.07,
        "y": 0.64
      },
      "kind": "list",
      "text": "Further, Cerevel's darigabat (a similar molecule) also missed the primary endpoint in the truncated GAD study and showed promising results in two Phase 1b studies in epilepsy and acute anxiety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c41580bd-2c94-42ad-8a6e-e095ce43dc1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "list",
      "text": "Side effects were mild or moderate with the most common side effects being dizziness and somnolence",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d815d85a-c7c2-4cf5-ab38-cefcfe7fcdaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca completed 10 clinical studies and demonstrated safety across trials",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28c1e9c6-e569-43dc-a7de-57d127899148",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}